Puma Biotechnology (PBYI) Current Assets (2010 - 2026)

Puma Biotechnology has reported Current Assets for 17 years, with the latest figure at $142.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 7.36% year-over-year to $142.3 million; the trailing twelve-month figure through Mar 2026 stood at $142.3 million (up 7.36% YoY), and the FY2025 full-year result was $162.7 million, up 10.18% from the prior year.
• Current Assets for Q1 2026 stood at $142.3 million, down from $162.7 million in the prior quarter.
• The five-year high for Current Assets was $162.7 million in Q4 2025, with the low at $111.8 million in Q1 2023.
• Historically, Current Assets has averaged $135.5 million across 5 years, with a median of $136.6 million in 2025.
• Annual changes were most pronounced in 2022 — Current Assets tumbled 31.88% — and 2024, when it increased 27.98%.
• Puma Biotechnology's Current Assets stood at $134.3 million in 2022, then climbed by 16.31% to $156.2 million in 2023, then dropped by 5.46% to $147.7 million in 2024, then rose by 10.18% to $162.7 million in 2025, then retreated by 12.56% to $142.3 million in 2026.
• The last three Current Assets figures came in at $142.3 million (Q1 2026), $162.7 million (Q4 2025), and $143.6 million (Q3 2025), per Business Quant data.